Who makes LNK01004 ointment 1.5%?

LNK01004 ointment 1.5% is developed by Lynk Pharmaceuticals Co., Ltd.

What development phase is LNK01004 ointment 1.5% in?

LNK01004 ointment 1.5% is in Phase 1.

Last reviewed 2026-04-19 · How we verify

LNK01004 ointment 1.5%

Lynk Pharmaceuticals Co., Ltd · Phase 1 active Small molecule

At a glance

Generic name	LNK01004 ointment 1.5%
Sponsor	Lynk Pharmaceuticals Co., Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LNK01004 ointment 1.5% CI brief — competitive landscape report
LNK01004 ointment 1.5% updates RSS · CI watch RSS
Lynk Pharmaceuticals Co., Ltd portfolio CI